These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25688516)

  • 1. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
    Frascaroli M; Di Cesare P
    Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
    Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
    Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 4. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report of a long-surviving man with metastatic renal cell carcinoma treated with pazopanib.
    Ratta R; Santini D
    Tumori; 2014; 100(2):e59-62. PubMed ID: 24852879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
    Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term response to pazopanib in an elderly man with mRCC. A case report.
    D'Aniello C; Cavaliere C; Pisconti S; Facchini G
    Tumori; 2014; 100(6):e305-8. PubMed ID: 25688517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES.
    Schmidinger M; Wittes J
    Curr Opin Urol; 2015 Sep; 25(5):395-401. PubMed ID: 26148069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
    Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
    Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
    [No Abstract]   [Full Text] [Related]  

  • 18. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
    Jo J; Kim JH; Kim JY; Hyun C; Rhee J; Kwon J; Han S; Kim W
    Cancer Res Treat; 2016 Jan; 48(1):393-7. PubMed ID: 25715772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.